Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing

Neuro-Oncology

Volumn 12, Issue 4, 2010, Pages 366-376

  Hashizume, Rintaro ^a,b   Gupta, Nalin ^a,b   Berger, Mitchel S ^a,b   Banerjee, Anu ^a,b   Prados, Michael D ^a,b   Ayers Ringler, Jennifer ^a,b   James, C David ^a,b   VandenBerg, Scott R ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atypical teratoid rhabdoid tumor; Bioluminescence; INI1; Orthotopic; Xenograft

Indexed keywords

BIOLOGICAL MARKER; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; EPITHELIAL MEMBRANE ANTIGEN; ETOPOSIDE; FIREFLY LUCIFERASE; GLIAL FIBRILLARY ACIDIC PROTEIN; IRINOTECAN; METHOTREXATE; PROTEIN S 100; SMOOTH MUSCLE ACTIN; TEMOZOLOMIDE; VINCRISTINE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATYPICAL TERATOID RHABDOID TUMOR; BIOLUMINESCENCE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CELL STRAIN; CELL STRAIN 293 T; CELL STRAIN BT 12; CELL STRAIN BT 16; CELL STRAIN GT 2; CELL STRUCTURE; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CONTROLLED STUDY; FATALITY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFANT; MOUSE; NONHUMAN; NUDE MOUSE; ORTHOTOPIC TRANSPLANTATION; POLYMERASE CHAIN REACTION; REPEATED DRUG DOSE; RHABDOID TUMOR; TRANSIENT TRANSFECTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; DRUG SCREENING; MALE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; INFANT; MALE; MICE; MICE, NUDE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954632253     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop033     Document Type: Article

References (41)

1. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001;17:503-511.
2. Lafay-Cousin L, Keene D, Carret A-S, et al. CNS atypical teratoid rhabdoid tumor (ATRT) in children less then 36 months: a Canadian Pediatric Brain Tumor Consortium (CPBTC) experience. Abstracts from the Thirteenth International Symposium on Pediatric Neuro-Oncology, June 29-July 2, 2008, Chicago, Illinois. Neuro-Oncology. 2008.
3. Hilden JM, Watterson J, Longee DC, et al. Central nervous system atypical teratoid tumor/rhabdoid tumor: response to intensive therapy and review of the literature. J Neurooncol. 1998;40(3):265-275.
4. Packer RJ, Biegel JA, Blaney S, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002;24:337-342.
5. Oka H, Scheithauer BW. Clinicopathological characteristics of atypical teratoid/rhabdoid tumor. Neurol Med Chir (Tokyo). 1999;39:510-517.
6. Oka H, Fujii K. Clinical features of atypical teratoid/rhabdoid tumor in Japan. Abstracts from the Thirteenth International Symposium on Pediatric Neuro-Oncology, June 29-July 2, 2008, Chicago, Illinois. Neuro-Oncology. 2008.
7. Rorke LB, Packer RJ, Biegel JA. 1996 Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg. 1996;85(1):56-65.
8. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol. 1998;22:1083-1092.
9. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74-79.
10. Biegel JA, Pollack AI. Molecular analysis of pediatric brain tumors. Curr Oncol Rep. 2004;6:445-452.
11. Judkins AR. Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol. 2007;14:335-339.
12. Takei H, Bhattacharjee MB, Rivera A, Dancer Y, Powell SZ. New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. Arch Pathol Lab Med. 2007;131:234-241.
13. Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;23:1491-1499.
14. Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol. 2004;22:2877-2884.
15. Strother D. Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther. 2005;5:907-915.
16. Meyers SP, Khademian ZP, Biegel JA, et al. Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes. Am J Neuroradiol. 2006;27:962-971.
17. Chen YW, Wong TT, Ho DM, et al. Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int J Radiat Oncol Biol Phys. 2006;64:1038-1043.
18. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27:385-389.
19. Houghton PJ, Adamson PC, Blaney S, et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002;8:3646-3657.
20. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005;7:164-176.
21. Günther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008;27:2897-2909.
22. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007;6:1167-1174.
23. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
24. Kleihues, P, Cavenee, WK, eds. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000.
25. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215-225.
26. Bouffard J-P, Sandberg GD, Golden JA, Rorke LJ. Double immunolabeling of central nervous system atypical teratoid/rhabdoid tumors. Mod Pathol. 2004;17:679-683.
27. Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/ rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin Cancer Res. 2002;8:3461-3467.
28. Versteege I, Medjkane S, Rouillard D, Delattre O. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene. 2002;21:6403-6412.
29. Caramel J, Medjkane S, Quignon F, Delattre O. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Oncogene. 2008;27:2035-2044.
30. Biegel JA, Kalpana G, Knudsen ES, et al. The role of INI-1 and the SWI/ SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res. 2002;62:323-328.
31. Muhlisch J, Schwering A, Grotzer M, et al. Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene. 2006;25:1111-1117.
32. Oruetxebarria I, Venturini F, Kekarainen T, et al. p16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem. 2004;279: 3807-3816.
33. Daniel Y, Wu DY, Tkachuck DC, et al. The human SNF5/INI1 protein facilitates the function of the growth arrest and DNA damage-inducible protein (GADD34) and modulates GADD34-bound protein phosphatase-1 activity. J Biol Chem. 2002;277:27706-27715.
34. Cao Y, Cairns BR, Kornberg RD, Laurent BC. Sfh1p, a component of a novel chromatin-remodeling complex, is required for cell cycle progression. Mol Cell Biol. 1997;17:3323-3334.
35. Zhang ZK, Davies KP, Allen J, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol. 2002;22:5975-5988.
36. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene. 2002;21:5193-5203.
37. Narendran A, Coppes L, Jayanthan A, et al. Establishment of atypicalteratoid/ rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. J Neurooncol. 2008;90:171-180.
38. D'Cunja J, Shalaby T, Rivera P, et al. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer. 2007;43:1581-1589.
39. Arcaro A, Doepfner KT, Boller D, et al. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem J. 2007;406:57-66.
40. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer. 2007;120:1787-1794.
41. Yachnis AT, Neubauer D, Muir D. Characterization of a primary central nervous system atypical teratoid/rhabdoid tumor and derivative cell line: immunophenotype and neoplastic properties. J Neuropathol Exp Neurol. 1998;57:961-971.